专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07259146B2 Neuroprotective peptides 有权
标题翻译：神经保护肽
公开(公告)号：US07259146B2
公开(公告)日：2007-08-21
申请号：US09863600
申请日：2001-05-23
申请人： Virginia Smith-Swintosky , Michael Renzi , Carlos Plata-Salaman , Linda Jolliffe , Francis Farrell , Dana Johnson
发明人： Virginia Smith-Swintosky , Michael Renzi , Carlos Plata-Salaman , Linda Jolliffe , Francis Farrell , Dana Johnson
IPC分类号： A61K38/00 , C07K16/00
CPC分类号： C07K14/505 , A61K38/00
摘要： Methods of treating diseases of the nervous system by administration of compositions having the neurological therapeutic activity of human erythropoietin are disclosed. These compositions include therapeutic agents such as peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity of human erythropoietin or only certain biological activities of erythropoietin. Improved therapeutic regimens where the erythropoietin is administered at concentrations below those required to stimulate hematopoiesis are also provided.
摘要翻译：公开了通过施用具有人促红细胞生成素神经学治疗活性的组合物治疗神经系统疾病的方法。这些组合物包括治疗剂，例如肽，肽二聚体，多肽和蛋白质，其具有人类促红细胞生成素的全部生物学活性或只有促红细胞生成素的某些生物学活性。还提供了改善的促红细胞生成素以低于刺激造血所需浓度的浓度给药的治疗方案。

2. 发明申请

US20090170759A1 NEUROPROTECTIVE PEPTIDES 审中-公开
标题翻译：神经保护肽
公开(公告)号：US20090170759A1
公开(公告)日：2009-07-02
申请号：US11776003
申请日：2007-07-11
申请人： Virginia Smith-Swintosky , Michael Renzi , Carlos Plata-Salaman , Linda Jolliffe , Francis Farrell , Dana Johnson
发明人： Virginia Smith-Swintosky , Michael Renzi , Carlos Plata-Salaman , Linda Jolliffe , Francis Farrell , Dana Johnson
IPC分类号： A61K38/16 , A61K38/10 , A61K38/08 , C12N5/06
CPC分类号： A61K38/1816 , A61K47/60 , C07K14/505
摘要： Methods of treating diseases of the nervous system by administration of compositions having the neurological therapeutic activity of human erythropoietin are disclosed. These compositions include therapeutic agents such as peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity of human erythropoietin or only certain biological activities of erythropoietin. Improved therapeutic regimens where the erythropoietin is administered at concentrations below those required to stimulate hematopoiesis are also provided.
摘要翻译：公开了通过施用具有人促红细胞生成素神经学治疗活性的组合物治疗神经系统疾病的方法。这些组合物包括治疗剂，例如肽，肽二聚体，多肽和蛋白质，其具有人类促红细胞生成素的全部生物学活性或只有促红细胞生成素的某些生物学活性。还提供了改善的促红细胞生成素以低于刺激造血所需浓度的浓度给药的治疗方案。

3. 发明申请

US20070065885A1 METHODS FOR SHP1 MEDIATED NEUROPROTECTION 审中-公开
标题翻译： SHP1介导的神经保护方法
公开(公告)号：US20070065885A1
公开(公告)日：2007-03-22
申请号：US11530234
申请日：2006-09-08
申请人： Michael Renzi , Navneeth Thirumalai , Linda Jolliffe , Francis Farrell
发明人： Michael Renzi , Navneeth Thirumalai , Linda Jolliffe , Francis Farrell
IPC分类号： G01N33/567 , G01N33/53
CPC分类号： G01N33/573 , A61K31/00 , A61K31/381 , A61K31/426 , A61K31/427 , A61K38/1816 , C12Q1/44 , G01N2500/02 , G01N2500/04 , G01N2500/10 , A61K2300/00
摘要： The effect of EPO on the phosphorylation of the EPO receptor, the activation of the MAP Kinase pathway, and the expression of SHP-1 were analyzed. EPO was observed to cause a decrease in the expression of its negative regulator SHP-1. The decrease observed at both the mRNA and protein level was dose dependent and persisted as long as 24 hr following EPO treatment. EPO can down regulate the expression of its own negative regulator as a means for increased potency in neurons. Assays were generated to identify compounds that are useful in regulating SHP1 activity in neural cells.
摘要翻译：分析EPO对EPO受体的磷酸化，MAP激酶途径的激活和SHP-1的表达的影响。观察到EPO引起其负调节物SHP-1的表达降低。在mRNA和蛋白质水平上观察到的降低是剂量依赖性的，并且在EPO处理后长达24小时持续。 EPO可以下调其自身负调节因子的表达，作为增加神经元效力的手段。产生测定以鉴定可用于调节神经细胞中SHP1活性的化合物。

4. 发明申请

US20070009967A1 METHODS FOR SHP1 MEDIATED NEUROPROTECTION 审中-公开
公开(公告)号：US20070009967A1
公开(公告)日：2007-01-11
申请号：US11530222
申请日：2006-09-08
申请人： Michael RENZI , Navneeth Thirumalai , Linda Jolliffe , Francis Farrell
发明人： Michael RENZI , Navneeth Thirumalai , Linda Jolliffe , Francis Farrell
IPC分类号： G01N33/567 , G01N33/53
CPC分类号： G01N33/573 , A61K31/00 , A61K31/381 , A61K31/426 , A61K31/427 , A61K38/1816 , C12Q1/44 , G01N2500/02 , G01N2500/04 , G01N2500/10 , A61K2300/00
摘要： The effect of EPO on the phosphorylation of the EPO receptor, the activation of the MAP Kinase pathway, and the expression of SHP-1 were analyzed. EPO was observed to cause a decrease in the expression of its negative regulator SHP-1. The decrease observed at both the mRNA and protein level was dose dependent and persisted as long as 24 hr following EPO treatment. EPO can down regulate the expression of its own negative regulator as a means for increased potency in neurons. Assays were generated to identify compounds that are useful in regulating SHP1 activity in neural cells.

5. 发明申请

US20110091378A1 Methods and Compositions for Treating Fibrosis Related Disorders Using IL-17 Antagonists 审中-公开
标题翻译：使用IL-17拮抗剂治疗纤维化相关疾病的方法和组合
公开(公告)号：US20110091378A1
公开(公告)日：2011-04-21
申请号：US12670179
申请日：2008-07-21
申请人： Paul Dudas , Sarah Sague , Merle M. Elloso , Francis Farrell
发明人： Paul Dudas , Sarah Sague , Merle M. Elloso , Francis Farrell
IPC分类号： A61K51/10 , A61K38/16 , A61K38/02 , A61K39/395 , A61P37/02 , A61P9/00 , A61P25/00
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/76
摘要： The present invention relates methods and compositions for treating interleukin-17 (IL-17) related conditions, such as IL-17A or IL-17F, or muteins thereof in patients having fibrosis using IL-17 antagonists, such as small molecule IL-17 antagonists or protein IL-17 antagonists, such as antibodies, including specified portions or variants, specific for at least one IL-17 protein, mutein or fragment thereof, including therapeutic formulations, administration and devices.
摘要翻译：本发明涉及使用IL-17拮抗剂（例如小分子IL-17）治疗患有纤维化的患者中的白细胞介素-17（IL-17）相关病症如IL-17A或IL-17F或其突变蛋白的方法和组合物拮抗剂或蛋白质IL-17拮抗剂，例如对于至少一种IL-17蛋白，突变蛋白或其片段特异性的包括特定部分或变体的抗体，包括治疗剂型，给药和装置。

6. 发明申请

US20110071277A1 RESISTIN ANTAGONISTS AND THEIR USE 审中-公开
标题翻译：电阻拮抗剂及其使用
公开(公告)号：US20110071277A1
公开(公告)日：2011-03-24
申请号：US12722950
申请日：2010-03-12
申请人： Simon Blake , Jill Carton , Jennifer Henrica Lee , Keying Ma , Paul Marsters , Kristen Picha , Xiao-Yu R. Song , Francis Farrell , Lynne Murray , Alexey Teplyakov , Tatiana Ort
发明人： Simon Blake , Jill Carton , Jennifer Henrica Lee , Keying Ma , Paul Marsters , Kristen Picha , Xiao-Yu R. Song , Francis Farrell , Lynne Murray , Alexey Teplyakov , Tatiana Ort
IPC分类号： C07K16/00
CPC分类号： C07K16/26 , C07K2317/34 , C07K2317/76 , C07K2317/92
摘要： Resistin antagonists, including antibodies reactive with defined epitopes, are disclosed. Antigens useful for raising antibodies against human resistin are also disclosed. Methods of utilizing resistin antagonists to treat or alleviate the symptoms of the diseases with aberrant fibroblast activity including interstitial lung diseases, hypertrophic scarring, keloid scarring and scleroderma are also disclosed. Methods of utilizing resistin as a biomarker to diagnose the risk and/or progression of osteoarthritis are also disclosed. Further disclosed are methods of utilizing the antagonists to treat or alleviate the symptoms of osteoarthritis.
摘要翻译：公开了抵抗素拮抗剂，包括与限定的表位反应的抗体。还公开了可用于提高抗人抵抗素抗体的抗原。还公开了利用抵抗素拮抗剂治疗或缓解具有异常成纤维细胞活性（包括间质性肺病，肥大性瘢痕形成，瘢痕疙瘩瘢痕形成和硬皮病）的疾病症状的方法。还公开了利用抗性蛋白作为生物标志物来诊断骨关节炎的风险和/或进展的方法。进一步公开的是利用拮抗剂治疗或减轻骨关节炎症状的方法。

7. 发明授权

US07232797B2 Erythropoietin dosing regimen for treating anemia 有权
标题翻译：用于治疗贫血的红细胞生成素给药方案
公开(公告)号：US07232797B2
公开(公告)日：2007-06-19
申请号：US10304382
申请日：2002-11-26
申请人： Francis Farrell , Linda K. Jolliffe
发明人： Francis Farrell , Linda K. Jolliffe
IPC分类号： A61K38/00 , C07K14/00 , C07K14/505
CPC分类号： A61K38/1816 , Y10S514/814
摘要： The present invention provides a new subcutaneous injection dosing regimen for erythropoietin to treat anemia. The new erythropoietin treatment regimen of the present invention results in improved hemoglobin levels with less frequent dosing.
摘要翻译：本发明提供了用于促红细胞生成素治疗贫血的新的皮下注射给药方案。本发明的新的促红细胞生成素治疗方案导致血红蛋白水平的改善，而不太频繁的给药。

8. 发明申请

US20050159442A1 Protein tyrosine phosphatase 1B (PTP-1B) inhibitors and methods of using the same 审中-公开
标题翻译：蛋白酪氨酸磷酸酶1B（PTP-1B）抑制剂及其使用方法
公开(公告)号：US20050159442A1
公开(公告)日：2005-07-21
申请号：US10975813
申请日：2004-10-28
申请人： Danlin Xu , Francis Farrell , Eugene Grant , Frank Brown
发明人： Danlin Xu , Francis Farrell , Eugene Grant , Frank Brown
IPC分类号： A61K31/445 , A61K31/4745 , A61K31/60 , C07D471/04
CPC分类号： C07D471/04 , A61K31/445 , A61K31/4745 , A61K31/60
摘要： A novel class of compounds has been identified that inhibit PTP-1B through a newly discovered binding interaction. Methods of treating, preventing or delaying the onset of, conditions mediated by PTP-1B are also provided. The compounds are capable of interacting with the primary binding pocket of PTP-1B via a hydrogen bond acceptor and have an aqueous phase free energy more positive than about −1200 kJ/mol. Representative compounds in the class are those of Formula I: or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug or metabolite form, or a pharmaceutically acceptable salt thereof, wherein R1, R2 and/or R3 are independently hydrogen atoms or alkyl groups and G1 and G2 are aryl, heteroaryl, alkyl, arylalkanyl, arylalkenyl, arylalkynyl, heteroarylalkanyl, heteroarylalkenyl, or heteroarylalkynyl moieties.
摘要翻译：已经鉴定出新类化合物通过新发现的结合相互作用抑制PTP-1B。还提供了治疗，预防或延缓由PTP-1B介导的病症发作的方法。该化合物能够通过氢键受体与PTP-1B的主要结合口相互作用，并且具有比约-1200kJ / mol更正的水相游离能。该类中的代表性化合物是式I的那些：或其旋光异构体，对映体，非对映异构体，外消旋体或外消旋混合物，酯，前药或代谢物形式或其药学上可接受的盐，其中R 1， R 2和/或R 3独立地是氢原子或烷基，G 1和G 2是芳基，杂芳基，烷基，芳基烷基，芳基烯基，芳基炔基，杂芳基烷基，杂芳基烯基或杂芳基炔基部分。

9. 发明申请

US20100183620A1 COMPOSITIONS AND METHODS FOR REGULATING COLLAGEN AND SMOOTH MUSCLE ACTIN EXPRESSION BY SERPINE2 审中-公开
标题翻译： SERPINE2调节胶原和丝氨酸肌酸激酶表达的组合物和方法
公开(公告)号：US20100183620A1
公开(公告)日：2010-07-22
申请号：US12626534
申请日：2009-11-25
申请人： KAUMUDI BHAWE , Elizabeth Bosch , Kathleen Boyle , Arthur Brace , Anuk Das , Francis Farrell , Pitchumani Sivakumar , Jeffrey Finer , Kristen Pierce , Kathleen M. Sullivan , Brian Wong
发明人： KAUMUDI BHAWE , Elizabeth Bosch , Kathleen Boyle , Arthur Brace , Anuk Das , Francis Farrell , Pitchumani Sivakumar , Jeffrey Finer , Kristen Pierce , Kathleen M. Sullivan , Brian Wong
IPC分类号： A61K39/395 , A61K31/7088 , A61K38/02 , A61K38/16 , A61P21/00 , C12Q1/68
CPC分类号： C07K14/811 , A61K38/57 , C07K16/38 , C07K2317/76
摘要： The invention encompasses methods and compositions for increasing or decreasing collagen 1A1 expression and/or α-smooth muscle actin expression in lung fibroblasts using SERPINE2 and antagonists of SERPINE2. The invention also encompasses methods and compositions for increasing or decreasing the formation of myofibroblasts. The invention further provides methods and compositions for treatment of lung diseases, such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease.
摘要翻译：本发明包括使用SERPINE2和SERPINE2拮抗剂增加或减少肺成纤维细胞中胶原1A1表达和/或α-平滑肌肌动蛋白表达的方法和组合物。本发明还包括用于增加或减少肌成纤维细胞形成的方法和组合物。本发明进一步提供了治疗肺部疾病如特发性肺纤维化和慢性阻塞性肺疾病的方法和组合物。

10. 发明申请

US20090117122A1 Resistin Antagonists and Their Use 审中-公开
标题翻译：抵抗拮抗剂及其用途
公开(公告)号：US20090117122A1
公开(公告)日：2009-05-07
申请号：US12233683
申请日：2008-09-19
申请人： Jill Carton , Francis Farrell , Lynne Murray , Tatiana Ort , Alexey Teplyakov
发明人： Jill Carton , Francis Farrell , Lynne Murray , Tatiana Ort , Alexey Teplyakov
IPC分类号： A61K39/395 , C07K16/18 , C07K7/08 , C07H21/00
CPC分类号： C07H21/04 , A61K2039/505 , C07K16/26 , C07K2317/34 , C07K2317/76 , C07K2317/92
摘要： Resistin antagonists, including antibodies reactive with defined epitopes, are disclosed. Methods of utilizing resistin antagonists to treat or alleviate the symptoms of the diseases with aberrant fibroblast activity including interstitial lung diseases, hypertrophic scarring, keloid scarring and scleroderma are also disclosed. Antigens useful for raising antibodies against human resistin are also disclosed.
摘要翻译：公开了抗性拮抗剂，包括与限定的表位反应的抗体。还公开了利用抵抗素拮抗剂治疗或缓解具有异常成纤维细胞活性（包括间质性肺病，肥大性瘢痕形成，瘢痕疙瘩瘢痕形成和硬皮病）的疾病症状的方法。还公开了可用于提高抗人抵抗素抗体的抗原。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式